Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC

Posted by Geri Gentry on Jun 8th, 2026

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research note issued on Monday,Benzinga reports. They currently have a $41.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 492.40% from the stock’s previous close.

A number of other research analysts also recently issued reports on ARTV. Wedbush raised their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. HC Wainwright increased their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Read Our Latest Stock Analysis on Artiva Biotherapeutics

Artiva Biotherapeutics Stock Up 1.0%

NASDAQ:ARTV traded up $0.07 during mid-day trading on Monday, reaching $6.92. 308,960 shares of the stock were exchanged, compared to its average volume of 321,188. The company has a 50 day simple moving average of $8.74 and a 200-day simple moving average of $6.01. The stock has a market capitalization of $171.07 million, a P/E ratio of -1.96 and a beta of 2.38. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, research analysts predict that Artiva Biotherapeutics will post -2.45 EPS for the current year.

Insider Activity at Artiva Biotherapeutics

In other news, SVP Heather Raymon sold 3,095 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total value of $27,885.95. Following the completion of the sale, the senior vice president directly owned 148,228 shares of the company’s stock, valued at $1,335,534.28. This trade represents a 2.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Subhashis Banerjee sold 7,037 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $63,403.37. Following the completion of the sale, the insider directly owned 144,963 shares of the company’s stock, valued at $1,306,116.63. This represents a 4.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders acquired 7,942,707 shares of company stock worth $91,499,985 and sold 53,040 shares worth $477,890. Insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds have recently modified their holdings of the business. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics during the second quarter worth $79,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics during the second quarter worth $58,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics during the second quarter worth $67,000. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics during the second quarter worth $53,000. Finally, BNP Paribas Financial Markets raised its holdings in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the last quarter.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.